Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Illumina in $1.2 Billion Deal with Pacific Biosciences

November 1, 2018

NEW YORKCovington advised Illumina, Inc. in its announced $1.2 billion acquisition of Pacific Biosciences.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function, and the company’s products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. Pacific Biosciences, based on its novel Single Molecule, Real Time (SMRT®) technology, provides high accuracy, ultra-long reads for full genome sequencing. The acquisition complements Illumina sequencing solutions with accurate long read sequencing capabilities to answer a set of complex genomic questions.

The Covington corporate team included Scott Smith, Jack Bodner, Brad Chernin, Scott Naturman, and Tracy Blauweiss.

Share this article: